{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:55Z","timestamp":1791353755092,"version":"4.3.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00223-011-9499-8","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T02:41:29Z","timestamp":1307068889000},"page":"91-104","source":"Crossref","is-referenced-by-count":172,"title":["Adverse Reactions and Drug\u2013Drug Interactions in the Management of Women with Postmenopausal Osteoporosis"],"prefix":"10.1007","volume":"89","author":[{"given":"Ren\u00e9","family":"Rizzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Br\u00e9art","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Diez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,3]]},"reference":[{"key":"9499_CR1","unstructured":"International Osteoporosis Foundation (2009) Facts and statistics about osteoporosis and its implications. www.iofbonehealth.org\/facts-and-statistics.html . Cited 10 Aug 2009"},{"key":"9499_CR2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00198-003-1385-4","volume":"14","author":"LJ Melton III","year":"2003","unstructured":"Melton LJ III, Gabriel SE, Crowson CS et al (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383\u2013388","journal-title":"Osteoporos Int"},{"key":"9499_CR3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010\u20132018","journal-title":"Lancet"},{"key":"9499_CR4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u20131259","journal-title":"Lancet"},{"key":"9499_CR5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/B978-0-323-04107-2.50245-3","volume-title":"Decision making in medicine. An algorithmic approach","author":"MD Katz","year":"2010","unstructured":"Katz MD (2010) Evaluation of adverse drug reactions. In: Mushlin SB, Greene HL II (eds) Decision making in medicine. An algorithmic approach, 3rd edn. Mosby Elsevier, Philadelphia, pp 698\u2013699","edition":"3"},{"key":"9499_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329:15\u201319","journal-title":"BMJ"},{"key":"9499_CR7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4065\/84.7.632","volume":"84","author":"KA Kennel","year":"2009","unstructured":"Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84:632\u2013637","journal-title":"Mayo Clin Proc"},{"key":"9499_CR8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/BOR.0b013e32832ca433","volume":"21","author":"DH Solomon","year":"2009","unstructured":"Solomon DH, Rekedal L, Cadarette SM (2009) Osteoporosis treatments and adverse events. Curr Opin Rheumatol 21:363\u2013368","journal-title":"Curr Opin Rheumatol"},{"key":"9499_CR9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","volume":"30","author":"W Strampel","year":"2007","unstructured":"Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755\u2013763","journal-title":"Drug Saf"},{"key":"9499_CR10","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2008.12.004","volume":"122","author":"RR Recker","year":"2009","unstructured":"Recker RR, Lewiecki EM, Miller PD et al (2009) Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 122:S22\u2013S32","journal-title":"Am J Med"},{"key":"9499_CR11","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555\u20131565","journal-title":"J Clin Endocrinol Metab"},{"key":"9499_CR12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8:96\u2013110","journal-title":"Hormones (Athens)"},{"key":"9499_CR13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","volume":"86","author":"B Abrahamsen","year":"2010","unstructured":"Abrahamsen B (2010) Adverse effects of bisphosphonates. Calcif Tissue Int 86:421\u2013435","journal-title":"Calcif Tissue Int"},{"key":"9499_CR14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/qjmed\/hcq259","volume":"104","author":"R Rizzoli","year":"2011","unstructured":"Rizzoli R (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104:281\u2013300","journal-title":"QJM"},{"key":"9499_CR15","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","volume":"98","author":"RE Coleman","year":"2008","unstructured":"Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736\u20131740","journal-title":"Br J Cancer"},{"key":"9499_CR16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"9499_CR17","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"9499_CR18","unstructured":"European Medicines Agency (2009) Alendronate. Summary of product characteristics. http:\/\/www.emea.europa.eu . Cited 19 Jan 2010"},{"key":"9499_CR19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"9499_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"9499_CR21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"9499_CR22","unstructured":"Food and Drug Administration (2002) Risedronate. Description. http:\/\/www.fda.gov . Cited 11 Feb 2010"},{"key":"9499_CR23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut","year":"2004","unstructured":"Chesnut CH, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"9499_CR24","unstructured":"European Medicines Agency (2007) Ibandronate. Summary of product characteristics. http:\/\/www.emea.europa.eu . Cited 11 Feb 2010"},{"key":"9499_CR25","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"9499_CR26","unstructured":"European Medicines Agency (2008) Zoledronic acid. Summary of product characteristics. http:\/\/www.emea.europa.eu . Cited 4 Jan 2010"},{"key":"9499_CR27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","volume":"77","author":"B Cryer","year":"2002","unstructured":"Cryer B, Bauer DC (2002) Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77:1031\u20131043","journal-title":"Mayo Clin Proc"},{"key":"9499_CR28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","volume":"77","author":"H Taggart","year":"2002","unstructured":"Taggart H, Bolognese MA, Lindsay R et al (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77:262\u2013270","journal-title":"Mayo Clin Proc"},{"key":"9499_CR29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2\u00a0year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"9499_CR30","doi-asserted-by":"crossref","first-page":"c4444","DOI":"10.1136\/bmj.c4444","volume":"341","author":"J Green","year":"2010","unstructured":"Green J, Czanner G, Reeves G et al (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 341:c4444","journal-title":"BMJ"},{"key":"9499_CR31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","volume":"304","author":"CR Cardwell","year":"2010","unstructured":"Cardwell CR, Abnet CC, Cantwell MM et al (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657\u2013663","journal-title":"JAMA"},{"key":"9499_CR32","unstructured":"Bilezikian J, Klemes A, Siris E (2009) Esophageal cancer reports coincident with risedronate use. J Bone Miner Res 24(Suppl 1): Abstract A09001305. J Bone Miner Res. http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/Abstracts.aspx . Cited 12 Feb 2010"},{"key":"9499_CR33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc0808738","volume":"360","author":"DK Wysowski","year":"2009","unstructured":"Wysowski DK (2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:89\u201390","journal-title":"N Engl J Med"},{"key":"9499_CR34","unstructured":"Food and Drug Administration (2008) Information on bisphosphonates. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/Default.htm . Cited 25 Feb 2010"},{"key":"9499_CR35","unstructured":"Food and Drug Administration (2008) Severe pain with osteoporosis drugs. http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/psn\/transcript.cfm?show=73 . Cited 31 May 2010"},{"key":"9499_CR36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1359\/JBMR.0301230","volume":"19","author":"K Thompson","year":"2004","unstructured":"Thompson K, Rogers MJ (2004) Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 19:278\u2013288","journal-title":"J Bone Miner Res"},{"key":"9499_CR37","first-page":"144","volume":"7","author":"O Bock","year":"2007","unstructured":"Bock O, Boerst H, Thomasius FE et al (2007) Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 7:144\u2013148","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"9499_CR38","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C et al (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","journal-title":"Arthritis Rheum"},{"key":"9499_CR39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2474-10-113","volume":"10","author":"A Mak","year":"2009","unstructured":"Mak A, Cheung MW, Ho RC et al (2009) Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 10:113","journal-title":"BMC Musculoskelet Disord"},{"key":"9499_CR40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.091201","volume":"25","author":"M Pazianas","year":"2010","unstructured":"Pazianas M, Compston J, Huang CL (2010) Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 25:2\u201310","journal-title":"J Bone Miner Res"},{"key":"9499_CR41","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","volume":"356","author":"SR Cummings","year":"2007","unstructured":"Cummings SR, Schwartz AV, Black DM (2007) Alendronate and atrial fibrillation. N Engl J Med 356:1895\u20131896","journal-title":"N Engl J Med"},{"key":"9499_CR42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archinte.168.8.826","volume":"168","author":"SR Heckbert","year":"2008","unstructured":"Heckbert SR, Li G, Cummings SR et al (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826\u2013831","journal-title":"Arch Intern Med"},{"key":"9499_CR43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","volume":"336","author":"HT Sorensen","year":"2008","unstructured":"Sorensen HT, Christensen S, Mehnert F et al (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813\u2013816","journal-title":"BMJ"},{"key":"9499_CR44","first-page":"712","volume":"357","author":"R Karam","year":"2007","unstructured":"Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357:712\u2013713","journal-title":"N Engl J Med"},{"key":"9499_CR45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-200932030-00004","volume":"32","author":"YK Loke","year":"2009","unstructured":"Loke YK, Jeevanantham V, Singh S (2009) Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 32:219\u2013228","journal-title":"Drug Saf"},{"key":"9499_CR46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","volume":"22","author":"R Rizzoli","year":"2011","unstructured":"Rizzoli R, Akesson K, Bouxsein M et al (2011) Subtrochanteric fracture after long-term treatment with bisphosphonates. Osteoporos Int 22:373\u2013390","journal-title":"Osteoporos Int"},{"key":"9499_CR47","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267\u20132294","journal-title":"J Bone Miner Res"},{"key":"9499_CR48","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","volume":"20","author":"BA Lenart","year":"2009","unstructured":"Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353\u20131362","journal-title":"Osteoporos Int"},{"key":"9499_CR49","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"9499_CR50","unstructured":"Ding A (2010) The structural effect of bisphosphonate treatment leading to atypical hip fractures. www3.aaos.org\/eduction\/anmeet\/anmt2010\/podium\/podium.cfm?Prevent=241 . Cited 31 May 2010"},{"key":"9499_CR51","unstructured":"Gladnick B, Donnely E, Lorich DG et al (2010) The effects of long-term bisphosphonate use on bone quality. www3.aaos.org\/eduction\/anmeet\/anmt2010\/podium\/podium.cfm?Prevent=339 . Cited 31 May 2010"},{"key":"9499_CR52","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black DM, Kelly MP, Genant HK et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761\u20131771","journal-title":"N Engl J Med"},{"key":"9499_CR53","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","volume":"22","author":"AS Neviaser","year":"2008","unstructured":"Neviaser AS, Lane JM, Lenart BA et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346\u2013350","journal-title":"J Orthop Trauma"},{"key":"9499_CR54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2009.03581.x","volume":"72","author":"CV Odvina","year":"2010","unstructured":"Odvina CV, Levy S, Rao S et al (2010) Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 72:161\u2013168","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9499_CR55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00002018-200932090-00002","volume":"32","author":"K Ing-Lorenzini","year":"2009","unstructured":"Ing-Lorenzini K, Desmeules J, Plachta O et al (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32:775\u2013785","journal-title":"Drug Saf"},{"key":"9499_CR56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/030079904X20259","volume":"21","author":"R Recker","year":"2005","unstructured":"Recker R, Masarachia P, Santora A et al (2005) Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21:185\u2013194","journal-title":"Curr Med Res Opin"},{"key":"9499_CR57","unstructured":"Bilezikian J, Klemes A, Silverman S et al (2009) Subtrochanteric fracture reports coincident with risedronate use. J Bone Miner Res 24(Suppl 1): Abstract A09001333. J Bone Miner Res. http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/Abstracts.aspx . Cited 12 February 2010"},{"key":"9499_CR58","unstructured":"Lyles K, Colon-Emeric CS, Magaziner JS et al (2007) Efficacy and safety of zoledronic acid 5\u00a0mg in preventing fractures in men and women with prevalent hip fracture: The HORIZON-Recurrent Fracture Trial. http:\/\/www.asbmr.org\/Meetings\/PastAnnualMeetings.aspx . Cited 25 Feb 2010"},{"key":"9499_CR59","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","volume":"7","author":"CA Migliorati","year":"2006","unstructured":"Migliorati CA, Siegel MA, Elting LS (2006) Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7:508\u2013514","journal-title":"Lancet Oncol"},{"key":"9499_CR60","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","volume":"45","author":"P Lesclous","year":"2009","unstructured":"Lesclous P, Abi NS, Carrel JP et al (2009) Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 45:843\u2013852","journal-title":"Bone"},{"key":"9499_CR61","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","volume":"42","author":"R Rizzoli","year":"2008","unstructured":"Rizzoli R, Burlet N, Cahall D et al (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841\u2013847","journal-title":"Bone"},{"key":"9499_CR62","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753\u2013761","journal-title":"Ann Intern Med"},{"key":"9499_CR63","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"9499_CR64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","volume":"4","author":"CR Dunstan","year":"2007","unstructured":"Dunstan CR, Felsenberg D, Seibel MJ (2007) Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 4:42\u201355","journal-title":"Nat Clin Pract Oncol"},{"key":"9499_CR65","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00198-009-1003-1","volume":"24","author":"C Cooper","year":"2010","unstructured":"Cooper C, Steinbuch M, Stevenson R et al (2010) The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos Int 24:569\u2013577","journal-title":"Osteoporos Int"},{"key":"9499_CR66","doi-asserted-by":"crossref","first-page":"c246","DOI":"10.1136\/bmj.c246","volume":"340","author":"A Khan","year":"2010","unstructured":"Khan A (2010) Osteonecrosis of the jaw and bisphosphonates. BMJ 340:c246","journal-title":"BMJ"},{"key":"9499_CR67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14219\/jada.archive.2008.0017","volume":"139","author":"JT Grbic","year":"2008","unstructured":"Grbic JT, Landesberg R, Lin SQ et al (2008) Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139:32\u201340","journal-title":"J Am Dent Assoc"},{"key":"9499_CR68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0278-2391(08)01667-4","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA et al (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update. J Oral Maxillofac Surg 67:2\u201312","journal-title":"J Oral Maxillofac Surg"},{"key":"9499_CR69","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00198-009-1097-5","volume":"21","author":"P Musette","year":"2010","unstructured":"Musette P, Brandi ML, Cacoub P et al (2010) Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 21:723\u2013732","journal-title":"Osteoporos Int"},{"key":"9499_CR70","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","volume":"74","author":"S Boonen","year":"2008","unstructured":"Boonen S, Sellmeyer DE, Lippuner K et al (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74:641\u2013648","journal-title":"Kidney Int"},{"key":"9499_CR71","unstructured":"Miller PD, Leigh C, Ward P (2006) Renal tolerability of intravenous ibandronate allow administration by short injection. Abstract FR10455. Ann Rheum Dis. http:\/\/www.eular.org\/ . Cited 26 Feb 2010"},{"key":"9499_CR72","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, Mac Clung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"9499_CR73","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez TN et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745\u2013755","journal-title":"N Engl J Med"},{"key":"9499_CR74","unstructured":"Food and Drug Administration (2009) Background document for meeting of Advisory Committee for Reproductive Health Drugs (August 13, 2009) Denosumab. www.fda.gov . Cited 8 March 2010"},{"key":"9499_CR75","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00198-009-1145-1","volume":"21","author":"A Toulis","year":"2010","unstructured":"Toulis A, Anastasilakis D (2010) Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 21:1963\u20131964","journal-title":"Osteoporos Int"},{"key":"9499_CR76","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0029-1224109","volume":"41","author":"AD Anastasilakis","year":"2009","unstructured":"Anastasilakis AD, Toulis KA, Goulis DG et al (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41:721\u2013729","journal-title":"Horm Metab Res"},{"key":"9499_CR77","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","volume":"22","author":"S Ferrari-Lacraz","year":"2011","unstructured":"Ferrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 22:435\u2013446","journal-title":"Osteoporos Int"},{"key":"9499_CR78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00198-010-1177-6","volume":"22","author":"A Kyrgidis","year":"2011","unstructured":"Kyrgidis A, Toulis KA (2011) Denosumab-related osteonecrosis of the jaws. Osteoporos Int 22:369\u2013370","journal-title":"Osteoporos Int"},{"key":"9499_CR79","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","volume":"48","author":"KH Taylor","year":"2010","unstructured":"Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48:221\u2013223","journal-title":"Br J Oral Maxillofac Surg"},{"key":"9499_CR80","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"9499_CR81","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"9499_CR82","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","volume":"20","author":"ES Siris","year":"2005","unstructured":"Siris ES, Harris ST, Eastell R et al (2005) Skeletal effects of raloxifene after 8\u00a0years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:1514\u20131524","journal-title":"J Bone Miner Res"},{"key":"9499_CR83","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727\u20132741","journal-title":"JAMA"},{"key":"9499_CR84","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0002-9149(01)01685-X","volume":"88","author":"L Mosca","year":"2001","unstructured":"Mosca L, Barrett-Connor E, Wenger NK et al (2001) Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol 88:392\u2013395","journal-title":"Am J Cardiol"},{"key":"9499_CR85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125\u2013137","journal-title":"N Engl J Med"},{"key":"9499_CR86","unstructured":"European Medicines Agency (2008) Raloxifene. Summary of product characteristics. http:\/\/www.emea.europa.eu . Cited 4 Jan 2010"},{"key":"9499_CR87","unstructured":"European Medicines Agency (2009) Lasofoxifene. Summary of product characteristics. http:\/\/www.emea.europa.eu . Cited 3 June 2010"},{"key":"9499_CR88","unstructured":"European Medicines Agency (2009) Bazedoxifene. Summary of product characteristics. http:\/\/www.emea.europa.eu"},{"key":"9499_CR89","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/jwh.2008.1086","volume":"18","author":"EM Lewiecki","year":"2009","unstructured":"Lewiecki EM (2009) Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health 18:1615\u20131626","journal-title":"J Womens Health"},{"key":"9499_CR90","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK et al (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923\u20131934","journal-title":"J Bone Miner Res"},{"key":"9499_CR91","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","volume":"16","author":"DF Archer","year":"2009","unstructured":"Archer DF, Pinkerton JV, Utian WH et al (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109\u20131115","journal-title":"Menopause"},{"key":"9499_CR92","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","volume":"362","author":"SR Cummings","year":"2010","unstructured":"Cummings SR, Ensrud K, Delmas PD et al (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686\u2013696","journal-title":"N Engl J Med"},{"key":"9499_CR93","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMe0912847","volume":"362","author":"C Becker","year":"2010","unstructured":"Becker C (2010) Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med 362:752\u2013754","journal-title":"N Engl J Med"},{"key":"9499_CR94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5122(99)00090-0","volume":"34","author":"FJ Cohen","year":"2000","unstructured":"Cohen FJ, Lu Y (2000) Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 34:65\u201373","journal-title":"Maturitas"},{"key":"9499_CR95","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","volume":"21","author":"S Martino","year":"2005","unstructured":"Martino S, Disch D, Dowsett SA et al (2005) Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 21:1441\u20131452","journal-title":"Curr Med Res Opin"},{"key":"9499_CR96","unstructured":"De Villiers TJ, Kendler DL, Chines A et al (2009) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase III trial. J Bone Miner Res 24(Suppl 1): Abstract A09002793. J Bone Miner Res. http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/Abstracts.aspx . Cited 29 Dec 2009"},{"key":"9499_CR97","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00003495-200060020-00013","volume":"60","author":"D Clemett","year":"2000","unstructured":"Clemett D, Spencer CM (2000) Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60:379\u2013411","journal-title":"Drugs"},{"key":"9499_CR98","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","volume":"104","author":"D Grady","year":"2004","unstructured":"Grady D, Ettinger B, Moscarelli E et al (2004) Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 104:837\u2013844","journal-title":"Obstet Gynecol"},{"key":"9499_CR99","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/01.GME.0000151653.02620.89","volume":"12","author":"CS Duvernoy","year":"2005","unstructured":"Duvernoy CS, Kulkarni PM, Dowsett SA et al (2005) Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause 12:444\u2013452","journal-title":"Menopause"},{"key":"9499_CR100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/STROKEAHA.108.518621","volume":"40","author":"L Mosca","year":"2009","unstructured":"Mosca L, Grady D, Barrett-Connor E et al (2009) Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 40:147\u2013155","journal-title":"Stroke"},{"key":"9499_CR101","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.amjcard.2005.09.083","volume":"97","author":"K Ensrud","year":"2006","unstructured":"Ensrud K, Genazzani AR, Geiger MJ et al (2006) Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 97:520\u2013527","journal-title":"Am J Cardiol"},{"key":"9499_CR102","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1095\/biolreprod.102.003848","volume":"67","author":"KM Dhandapani","year":"2002","unstructured":"Dhandapani KM, Brann DW (2002) Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 67:1379\u20131385","journal-title":"Biol Reprod"},{"key":"9499_CR103","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1176\/appi.ajp.162.4.683","volume":"162","author":"K Yaffe","year":"2005","unstructured":"Yaffe K, Krueger K, Cummings SR et al (2005) Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 162:683\u2013690","journal-title":"Am J Psychiatry"},{"key":"9499_CR104","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.GME.0000058772.59606.2A","volume":"10","author":"EE Jolly","year":"2003","unstructured":"Jolly EE, Bjarnason NH, Neven P et al (2003) Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5\u00a0years. Menopause 10:337\u2013344","journal-title":"Menopause"},{"key":"9499_CR105","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.bone.2007.02.003","volume":"40","author":"PJ Marie","year":"2007","unstructured":"Marie PJ (2007) Strontium ranelate: new insights into its dual mode of action. Bone 40:S5\u2013S8","journal-title":"Bone"},{"key":"9499_CR106","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"9499_CR107","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"9499_CR108","unstructured":"European Medicines Agency (2009) Strontium ranelate. Summary of product characteristics. http:\/\/www.emea.europa.eu . Cited 3 June 2010"},{"key":"9499_CR109","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","volume":"5","author":"IA Naess","year":"2007","unstructured":"Naess IA, Christiansen SC, Romundstad P et al (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5:692\u2013699","journal-title":"J Thromb Haemost"},{"key":"9499_CR110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0037-1613887","volume":"83","author":"E Oger","year":"2000","unstructured":"Oger E (2000) Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBP Study Group. Groupe d\u2019Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83:657\u2013660","journal-title":"Thromb Haemost"},{"key":"9499_CR111","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","volume":"158","author":"MD Silverstein","year":"1998","unstructured":"Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 158:585\u2013593","journal-title":"Arch Intern Med"},{"key":"9499_CR112","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00198-009-1050-7","volume":"21","author":"G Breart","year":"2010","unstructured":"Breart G, Cooper C, Meyer O et al (2010) Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 21:1181\u20131187","journal-title":"Osteoporos Int"},{"key":"9499_CR113","first-page":"S94","volume":"20","author":"G Breart","year":"2009","unstructured":"Breart G, Audran M, Brandi ML et al (2009) Good safety and persistence of strontium ranelate in a prospective observational cohort study. Osteoporos Int 20:S94","journal-title":"Osteoporos Int"},{"key":"9499_CR114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-200831010-00001","volume":"31","author":"M Perrio","year":"2008","unstructured":"Perrio M, Wilton L, Shakir S (2008) Analysis of venous thromboembolism in the strontium ranelate prescription-event monitoring (PEM) cohort: interim results. Drug Saf 31:1","journal-title":"Drug Saf"},{"key":"9499_CR115","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.2165\/0003495-200868180-00012","volume":"68","author":"SK Blick","year":"2008","unstructured":"Blick SK, Dhillon S, Keam SJ (2008) Teriparatide: a review of its use in osteoporosis. Drugs 68:2709\u20132737","journal-title":"Drugs"},{"key":"9499_CR116","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"9499_CR117","unstructured":"European Medicines Agency (2008) Teriparatide. Summary of product characteristics. http:\/\/www.emea.europa.eu . Cited 11 Feb 2009"},{"key":"9499_CR118","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP et al (2007) Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326\u2013339","journal-title":"Ann Intern Med"},{"key":"9499_CR119","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","volume":"20","author":"C Deal","year":"2005","unstructured":"Deal C, Omizo M, Schwartz EN et al (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905\u20131911","journal-title":"J Bone Miner Res"},{"key":"9499_CR120","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2\u00a0years and relevance to human safety. Toxicol Pathol 30:312\u2013321","journal-title":"Toxicol Pathol"},{"key":"9499_CR121","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","volume":"32","author":"JL Vahle","year":"2004","unstructured":"Vahle JL, Long GG, Sandusky G et al (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426\u2013438","journal-title":"Toxicol Pathol"},{"key":"9499_CR122","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","volume":"22","author":"KD Harper","year":"2007","unstructured":"Harper KD, Krege JH, Marcus R et al (2007) Osteosarcoma and teriparatide? J Bone Miner Res 22:334","journal-title":"J Bone Miner Res"},{"key":"9499_CR123","unstructured":"Food and Drug Administration (2008) FORTEO teriparatide (rDNA origin) injection. http:\/\/www.fda.gov\/ . Cited 9 Feb 2010"},{"key":"9499_CR124","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00198-009-0891-4","volume":"20","author":"F Vries de","year":"2009","unstructured":"de Vries F, Cooper AL, Cockle SM et al (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20:1989\u20131998","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"9499_CR125","first-page":"S101","volume":"15","author":"F Bauss","year":"2010","unstructured":"Bauss F, Kling L, Worth E et al (2010) Drug\u2013drug interactions are unlikely with ibandronate. Abstract P374SU. Osteoporos Int 15(Suppl 1):S101","journal-title":"Osteoporos Int"},{"key":"9499_CR126","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00000441-200306000-00006","volume":"325","author":"MA Perazella","year":"2003","unstructured":"Perazella MA (2003) Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 325:349\u2013362","journal-title":"Am J Med Sci"},{"key":"9499_CR127","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1097\/CCM.0b013e318168e375","volume":"36","author":"N Pannu","year":"2008","unstructured":"Pannu N, Nadim MK (2008) An overview of drug-induced acute kidney injury. Crit Care Med 36:S216\u2013S223","journal-title":"Crit Care Med"},{"key":"9499_CR128","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0278-5846(82)80162-0","volume":"6","author":"CA Naranjo","year":"1982","unstructured":"Naranjo CA, Busto U, Sellers EM (1982) Difficulties in assessing adverse drug reactions in clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 6:651\u2013657","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9499_CR129","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2125.2007.02937.x","volume":"64","author":"Y Arimone","year":"2007","unstructured":"Arimone Y, Miremont-Salame G, Haramburu F et al (2007) Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol 64:482\u2013488","journal-title":"Br J Clin Pharmacol"},{"key":"9499_CR130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00228-008-0475-9","volume":"64","author":"L Harmark","year":"2008","unstructured":"Harmark L, van Grootheest AC (2008) Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 64:743\u2013752","journal-title":"Eur J Clin Pharmacol"},{"key":"9499_CR131","first-page":"63","volume":"2","author":"MJ Doherty","year":"2009","unstructured":"Doherty MJ (2009) Algorithms for assessing the probability of an adverse drug reaction. Respir Med 2:63\u201367","journal-title":"Respir Med"},{"key":"9499_CR132","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0140-6736(02)07923-0","volume":"359","author":"DC Berry","year":"2002","unstructured":"Berry DC, Knapp P, Raynor DK (2002) Provision of information about drug side-effects to patients. Lancet 359:853\u2013854","journal-title":"Lancet"},{"key":"9499_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-200326010-00001","volume":"26","author":"DC Berry","year":"2003","unstructured":"Berry DC, Raynor DK, Knapp P et al (2003) Patients\u2019 understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf 26:1\u201311","journal-title":"Drug Saf"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00223-011-9499-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T06:43:28Z","timestamp":1560235408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-011-9499-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,3]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["9499"],"URL":"https:\/\/doi.org\/10.1007\/s00223-011-9499-8","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,3]]}}}